You can buy or sell MRSN and other stocks, options, ETFs, and crypto commission-free!
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. Read More The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
-$0.37 per share
-$0.35 per share